We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
Tandem Diabetes Care, Inc. (TNDM - Free Report) reported $249.25 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 2.2%. EPS of -$0.31 for the same period compares to -$0.36 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $237.76 million, representing a surprise of +4.83%. The company has not delivered EPS surprise, with the consensus EPS estimate being -$0.31.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Tandem Diabetes Care performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Pump Shipments - Total Worldwide: 29,000 compared to the 29,264 average estimate based on two analysts.
Pump Shipments - Outside the United States: 9,000 versus 8,979 estimated by two analysts on average.
Pump Shipments - United States: 20,000 compared to the 20,285 average estimate based on two analysts.
Geographic Sales- United States: $175.63 million versus $175.5 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +2.3% change.
Geographic Sales- Outside the United States: $73.62 million versus the five-analyst average estimate of $69.87 million. The reported number represents a year-over-year change of +1.8%.
Sales- Pump- United States: $84.79 million compared to the $88.14 million average estimate based on five analysts. The reported number represents a change of -2.2% year over year.
Sales- Pump- Outside the United States: $25.33 million versus the five-analyst average estimate of $24.79 million. The reported number represents a year-over-year change of -9.8%.
Sales- Supplies and Other- United States: $90.85 million compared to the $87.37 million average estimate based on five analysts. The reported number represents a change of +8.3% year over year.
Sales- Supplies and Other- Outside the United States: $48.29 million versus $45.08 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +9.2% change.
Geographic Revenues- United States (Non-GAAP): $175.63 million compared to the $169.28 million average estimate based on two analysts.
Revenue- Supplies and Other: $139.14 million compared to the $130.06 million average estimate based on five analysts.
Revenue- Pump: $110.11 million compared to the $112.93 million average estimate based on five analysts.
Shares of Tandem Diabetes Care have returned -4.4% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say
Tandem Diabetes Care, Inc. (TNDM - Free Report) reported $249.25 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 2.2%. EPS of -$0.31 for the same period compares to -$0.36 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $237.76 million, representing a surprise of +4.83%. The company has not delivered EPS surprise, with the consensus EPS estimate being -$0.31.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Tandem Diabetes Care performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:View all Key Company Metrics for Tandem Diabetes Care here>>>
Shares of Tandem Diabetes Care have returned -4.4% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.